COVID resurge: Are pharma stocks the next big bet?

In this video, we cover 3 important developments:

1. Pharma Sector: A new COVID variant is quietly spreading, triggering interest in healthcare and diagnostic stocks. However, pharma stocks remain range-bound with no broad rally expected. Large-caps like Sun Pharma and Cipla are under pressure due to margin stress and weak US sales. Mid-caps like Ajanta and Glenmark are showing relative strength. Key triggers include USFDA approvals and risks like US tariffs.

2. Aviation Sector: Turkish firm Celebi’s exit from India has opened the runway for Adani Group to enter ground handling services, a largely ignored but high-potential segment. With presence across 8 airports and strategic hires, Adani is aiming to dominate every layer of airport operations, from terminals to tarmac.

3. IndiaAI Mission: The Indian government is backing four homegrown startups with infrastructure and compute power to develop large language models (LLMs) – India’s answer to ChatGPT. Startups like Sarvam AI and Soket AI are working on multimodal and open-source models. The mission aims to build AI tools rooted in Indian languages for real-world impact.